The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry

被引：0
|
作者：
Pappas, Dimitrios A. [1 ]
St John, Gregory [2 ]
Etzel, Carol J. [1 ]
Fiore, Stefano [3 ]
Blachley, Taylor [1 ]
Kimura, Toshio [2 ]
Punekar, Rajeshwari [3 ]
Emeanuru, Kelechi [1 ]
Boklage, Susan [2 ]
Kremer, Joel [1 ,4 ,5 ]
机构：
[1] Corrona LLC, Waltham, MA USA
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] Sanofi, Bridgewater, NJ USA
[4] Albany Med Coll, Albany, NY 12208 USA
[5] Ctr Rheumatol, Albany, NY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2877
引用
收藏
页数：2
相关论文
共 50 条
  • [31] DISCONTINUATION AND EFFECTIVENESS OF ORIGINATOR AND BIOSIMILAR TNFI IN PATIENTS WITH RHEUMATOID ARTHRITIS: REAL WORLD DATA FROM A RHEUMATOID ARTHRITIS REGISTRY IN CANADA
    Movahedi, M.
    Cesta, A.
    Li, X.
    Bombardier, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1381 - 1381
  • [32] Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
    James R. Spalding
    Joel Hay
    PharmacoEconomics, 2006, 24 : 1221 - 1232
  • [33] Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis
    Spalding, James R.
    Hay, Joel
    PHARMACOECONOMICS, 2006, 24 (12) : 1221 - 1232
  • [34] Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort
    Movahedi, Mohammad
    Hepworth, Elliot
    Mirza, Reza
    Cesta, Angela
    Larche, Maggie
    Bombardier, Claire
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (05) : 915 - 922
  • [35] THE EFFECT OF MEDICATION CHOICE AFTER TUMOR NECROSIS FACTOR INHIBITOR (TNFI) USE ON THE HEALTHCARE COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: AN INSTRUMENTAL VARIABLES APPROACH
    Shahabi, A.
    Shafrin, J.
    Zhao, L.
    Green, S.
    Marshall, A.
    Curtice, T.
    Paul, D.
    VALUE IN HEALTH, 2018, 21 : S195 - S196
  • [36] Cost-effectiveness of tumor necrosis factor alpha (TNF-alpha) inhibitors as first-line agents in rheumatoid arthritis
    Spalding, JR
    Hay, JW
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [37] THE COMPARATIVE EFFECTIVENESS OF CYCLING TUMOURNECROSIS FACTOR INHIBITOR (TNFI) VERSUS SWAPPING TO A NONTNFI ON PATIENT-REPORTED FUNCTIONAL ABILITY OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Lopez-Oliva, M. A.
    Matusevich, A.
    Cantor, S. B.
    Pratt, G.
    Suarez-Almazor, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 196 - 196
  • [38] Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
    Leslie R. Harrold
    George W. Reed
    Robert Magner
    Ashwini Shewade
    Ani John
    Jeffrey D. Greenberg
    Joel M. Kremer
    Arthritis Research & Therapy, 17
  • [39] Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
    Leslie R. Harrold
    Heather J. Litman
    Sean E. Connolly
    Evo Alemao
    Sheila Kelly
    Sabrina Rebello
    Winnie Hua
    Joel M. Kremer
    Rheumatology and Therapy, 2019, 6 : 217 - 230
  • [40] Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
    Harrold, Leslie R.
    Litman, Heather J.
    Connolly, Sean E.
    Alemao, Evo
    Kelly, Sheila
    Rebello, Sabrina
    Hua, Winnie
    Kremer, Joel M.
    RHEUMATOLOGY AND THERAPY, 2019, 6 (02) : 217 - 230
12345